FAQ (FAQ 411)
Foreo, Inc. · Decision date Oct 22, 2026
What did the FDA decide?
The FDA record for K261565 lists Foreo, Inc. of Las Vegas, Nevada, as applicant for a traditional 510(k) under the device name FAQ™ (FAQ 411). The listed decision is SESE, dated 2026-10-22, with a recorded submission date of 05/11/2026. The record carries product code NFO and specialty Neurology, and the review documentation is listed as a Summary. SESE denotes a 510(k) clearance rather than a PMA approval.
The source does not describe the device's components, intended use, technology, or any changed item, and it does not identify a predicate device or a relationship to another application. The excerpt also does not state the basis for the Neurology specialty or product code NFO assignment. No clinical, efficacy, or labeling conclusions can be drawn from these fields, and the substantive content of the Summary document remains unexamined here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Oct 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261565
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Foreo, Inc.
- Product code
- NFO
- Decision code
- SESE
- Decision date
- Oct 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, Transcutaneous Electrical, Aesthetic Purposes.
- Applicant
- Foreo, Inc.
- Product code
- NFO
- FDA device class
- 2
FDA decision timeline
K261565 received
Application receipt date recorded by FDA.
K261565 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NFO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FAQ (FAQ 401);FAQ (FAQ 402)K261625 | Foreo, Inc. | 510(k) clearance | Oct 26, 2026 | FDA |
| Guangdong Newdermo Biotech Co., Ltd. | 510(k) clearance | Sep 16, 2026 | FDA | |
PureLift Pro MaxK262861 | Xtreem Pulse, LLC | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Foreo, Inc.
- Headquarters
- Not reported
- Brand website
- foreo.com
- FDA applicant address
- Las Vegas, NV
Sources and methodology
- Original FDA record: K261565
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

